A new adenine base editing strategy reported in Gene Therapy corrected a splice mutation (IVS4+919; G>A) linked to cardiac-type Fabry disease in cells. The work centers on using ABE to restore the genetic message at a “cryptic” splice site and evaluate downstream functional rescue. The platform positions base editing as an approach for precisely repairing disease-relevant RNA splicing defects rather than introducing broader genome changes. For Fabry, which remains a high-burden lysosomal disorder with a complex genotype-to-phenotype link, the move targets a mutation class that can be difficult to address. Researchers framed the results as a step toward mutation-specific treatments, potentially informing future delivery choices, off-target monitoring plans, and whether correction translates into meaningful cellular phenotypes beyond the initial edit readout.